Lisata Therapeutics (NASDAQ:LSTA) Earns Buy Rating from HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 466.51% from the company’s current price.

Lisata Therapeutics Stock Performance

Shares of Lisata Therapeutics stock opened at $2.65 on Thursday. Lisata Therapeutics has a twelve month low of $1.95 and a twelve month high of $4.53. The business has a 50-day moving average price of $3.02 and a 200 day moving average price of $2.71.

Lisata Therapeutics (NASDAQ:LSTA) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.20. As a group, equities analysts expect that Lisata Therapeutics will post -3.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Lisata Therapeutics

An institutional investor recently raised its position in Lisata Therapeutics stock. BML Capital Management LLC raised its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 10.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 269,839 shares of the company’s stock after buying an additional 26,000 shares during the period. Lisata Therapeutics comprises about 0.6% of BML Capital Management LLC’s portfolio, making the stock its 24th largest holding. BML Capital Management LLC owned approximately 3.31% of Lisata Therapeutics worth $737,000 at the end of the most recent reporting period. Institutional investors own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.